Bortezomib will increase the stage or result of flibanserin by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Check. Increased flibanserin adverse results could manifest if coadministered with a number of weak CYP3A4 inhibitors. Essential: The drug information on this site is supposed to get instructional. It isn't a substitute for health https://finnseoxz.post-blogs.com/48167154/not-known-facts-about-lp-pla2-in-1